Calhoun Research Laboratory, Akron General Medical Center, Akron, OH 44307, USA.
Acta Biomater. 2013 Feb;9(2):5132-42. doi: 10.1016/j.actbio.2012.08.035. Epub 2012 Sep 10.
Materials currently used for the treatment of bone defects include ceramics, polymeric scaffolds and composites, which are often impregnated with recombinant growth factors and other bioactive substances. While these materials have seen instances of success, each has inherent shortcomings including prohibitive expense, poor protein stability, poorly defined growth factor release and less than desirable mechanical properties. We have developed a novel class of amino acid-based poly(ester urea)s (PEU) materials which are biodegradable in vivo and possess mechanical properties superior to conventionally used polyesters (<3.5 GPa) available currently to clinicians and medical providers. We report the use of a short peptide derived from osteogenic growth peptide (OGP) as a covalent crosslinker for the PEU materials. In addition to imparting specific bioactive signaling, our crosslinking studies show that the mechanical properties increase proportionally when 0.5% and 1.0% concentrations of the OGP crosslinker are added. Our results in vitro and in an in vivo subcutaneous rat model show the OGP-based crosslinkers, which are small fragments of growth factors that are normally soluble, exhibit enhanced proliferative activity, accelerated degradation properties and concentration dependent bioactivity when immobilized.
目前用于治疗骨缺损的材料包括陶瓷、聚合物支架和复合材料,这些材料通常用重组生长因子和其他生物活性物质浸渍。虽然这些材料已经取得了一定的成功,但每种材料都有其内在的缺点,包括费用过高、蛋白质稳定性差、生长因子释放不明确以及力学性能不理想等。我们开发了一类新型的氨基酸基聚酯脲(PEU)材料,这些材料在体内可生物降解,具有优于目前临床医生和医疗服务提供者使用的传统聚酯(<3.5 GPa)的力学性能。我们报告了使用源自成骨生长肽(OGP)的短肽作为 PEU 材料的共价交联剂。除了赋予特定的生物活性信号外,我们的交联研究表明,当添加 0.5%和 1.0%浓度的 OGP 交联剂时,力学性能成比例增加。我们的体外和体内皮下大鼠模型的结果表明,基于 OGP 的交联剂是生长因子的小片段,通常是可溶性的,当固定时表现出增强的增殖活性、加速的降解特性和浓度依赖性生物活性。